Search results for "MUCOSA"

showing 10 items of 1066 documents

Intestinal drug efflux: formulation and food effects

2001

The intestine, primarily regarded as an absorptive organ, is also prepared for the elimination of certain organic acids, bases and neutral compounds depending on their affinity to intestinal carrier systems. Several of the transport systems known to mediate efflux in the major clearing organs--liver and kidney--are also expressed in the intestine. Examples of secretory transporters in the intestine are P-glycoprotein, members of the multidrug resistance associated protein family, breast cancer resistance protein, organic cation transporters and members of the organic anion polypeptide family. In this communication, the P-glycoprotein mediated intestinal secretion of talinolol, a model compo…

Drug CarriersIntestinal permeabilityOrganic cation transport proteinsbiologyPharmaceutical ScienceIleummedicine.diseaseRatsJejunumFood-Drug Interactionsmedicine.anatomical_structureSecretory proteinIntestinal AbsorptionPharmaceutical PreparationsBiochemistrybiology.proteinmedicineAnimalsHumansEffluxIntestinal MucosaDrug metabolismP-glycoproteinAdvanced Drug Delivery Reviews
researchProduct

Biopartitioning micellar chromatography: an in vitro technique for predicting human drug absorption.

2001

The main oral drug absorption barriers are fluid cell membranes and generally drugs are absorbed by a passive diffusion mechanism. Biopartitioning micellar chromatography (BMC) is a mode of micellar liquid chromatography that uses micellar mobile phases of Brij35 under adequate experimental conditions and can be useful to mimic the drug partitioning process in biological systems. In this paper the usefulness of BMC for predicting oral drug absorption in humans is demonstrated. A hyperbolic model has been obtained using the retention data of a heterogeneous set of 74 compounds, which shows predictive ability for drugs absorbed by passive diffusion. The model obtained in BMC is compared with …

DrugAbsorption (pharmacology)ChromatographyFenbufenChemistryDrug discoverymedia_common.quotation_subjectAdministration OralGeneral ChemistryIn Vitro TechniquesIn vitroCell LineMembraneMicellar liquid chromatographymedicineHumansPharmacokineticsSpectrophotometry UltravioletIntestinal MucosaQuantitative analysis (chemistry)Micellesmedicine.drugmedia_commonChromatography LiquidJournal of chromatography. B, Biomedical sciences and applications
researchProduct

5-Fluorouracil Buccal Tablets for Locoregional Chemotherapy of Oral Squamous Cell Carcinoma: Formulation, Drug Release and Histological Effects on Re…

2010

5-Fluorouracil (5-FU) is currently used for treatment of oral squamous cell carcinoma (OSCC). 5-FU is given by i.v. although the systemic administration is associated with severe toxic effects and no topical formulations of 5-FU for buccal drug delivery have been reported. In this study we would report the development of buccal tablets suitable for direct application of low-doses of 5-FU on cancer lesions. The topical administration could be effective on tumor area while systemic undesired side effects are avoided. Preliminarily, the limited tendency of 5-FU to cross the buccal tissue was established using reconstituted human oral epithelium (RHOE, in vitro) and porcine buccal mucosa (ex vi…

DrugAntimetabolites AntineoplasticPathologymedicine.medical_specialtySwineChemistry PharmaceuticalDrug Compounding5-Fluorouracilmedia_common.quotation_subjectPharmaceutical ScienceApoptosisSettore MED/08 - Anatomia PatologicaLocoregional drug deliveryOral Squamous Cell CarcinomaPermeabilityTissue Culture TechniquesDrug Delivery SystemsSettore MED/28 - Malattie OdontostomatologicheCarcinomaAnimalsHumansMedicinemedia_commonbusiness.industryMouth MucosaAdministration BuccalCancerBuccal administrationmedicine.diseaseReconstituted Human Oral Epitheliumstomatognathic diseasesSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoFluorouracilDrug deliveryCarcinoma Squamous CellSystemic administrationMouth NeoplasmsFluorouracilPorcine buccal mucosaBuccal tabletsbusinessEx vivoTabletsmedicine.drugCurrent Drug Delivery
researchProduct

Alendronate-related oral mucosa ulcerations

2000

Alendronate is widely used in the treatment of osteoporosis and other bone diseases. Although it is considered a well-tolerated drug, there are numerous reports of adverse effects on the mucosa in the upper aerodigestive tract, with oesophagitis as the most common complication. The strict regulations for the proper administration of the drug indicate that these side effects might well be the result of a direct, irritant mechanism on the upper aerodigestive tract. We present two clinical cases of patients who developed extensive palatal ulcers as a result of taking alendronate. We discuss possible mechanisms implicated in the production of the ulcers and some clinical factors of interest.

DrugCancer Researchmedicine.medical_specialtyBone diseasebusiness.industryAlendronic acidmedia_common.quotation_subjectOsteoporosismedicine.diseaseDermatologyPathology and Forensic MedicineSurgerymedicine.anatomical_structureOtorhinolaryngologymedicinePeriodonticsOral SurgeryOral mucosaAdverse effectbusinessComplicationAdverse drug reactionmedicine.drugmedia_commonJournal of Oral Pathology & Medicine
researchProduct

Aloin delivery on buccal mucosa: ex vivo studies and design of a new locoregional dosing system

2014

Context: Chemoprevention of potential malignant disorders or cancerous lesions that affect oral mucosae requires extended duration of treatment. Locoregional delivery of natural products could represent a promising strategy for this purpose. Objective: To investigate the aptitude of aloin to permeate through, or accumulate in, the buccal mucosa and to develop a new prolonged oro-mucosal drug delivery system. Materials and Methods: Permeation/accumulation of aloin from Curacao Aloe (containing 50% barbaloin) was evaluated ex vivo, using porcine buccal mucosa as the most useful model to simulate human epithelium. Oro-mucosal matrix tablets were prepared by dispersing aloin (10% w/w) in Eudrag…

DrugEmodinPolymersSwinemedia_common.quotation_subjectChemistry PharmaceuticalAcrylic ResinsPharmaceutical ScienceDentistryAloinPharmacologyFriabilityPermeabilityBarbaloin buccal tablets aloin matrix tablets oro-mucosal delivery locoregional drug delivery buccal mucosa.chemistry.chemical_compoundDrug Delivery SystemsSettore MED/28 - Malattie OdontostomatologicheDrug DiscoverymedicineAnimalsDosingAloemedia_commonPharmacologybusiness.industryOrganic ChemistryMouth MucosaAdhesivenessReproducibility of ResultsPermeationDrug LiberationchemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliverySwellingmedicine.symptombusinessEx vivoTablets
researchProduct

Potential transbuccal delivery of l-DOPA methylester prodrug: stability in the environment of the oral cavity and ability to cross the mucosal tissue

2016

Levodopa (l-DOPA) is the most effective pharmacologic agent in Parkinson's disease and remains the "gold standard". Nevertheless, in long-term treatments, dyskinesias and motor complications can emerge. In this work, the combined use of l-DOPA methylester hydrochloride prodrug (LDME) with transbuccal drug delivery was supposed as a good alternative method to optimize the bioavailability of l-DOPA, to maintain constant plasma levels and to decrease the drug unwanted effects. The effects of environmental pH on buccal delivery of LDME were evaluated ex vivo. The increase of pH value from 5.8 to 6.2 implies an improvement of drug permeation. Since the pH increase causes the raising of hydrolyti…

DrugHydrochloridemedia_common.quotation_subjectPharmaceutical Science02 engineering and technologyPharmacologyAntiparkinson AgentsLevodopachemical stability03 medical and health scienceschemistry.chemical_compoundDrug Delivery Systems0302 clinical medicineDrug StabilitySettore MED/28 - Malattie OdontostomatologicheProdrugsmedia_commonBuccal permeationMouthintellidrug deviceMouth MucosaParkinson DiseaseGeneral MedicineBuccal administrationPermeationProdrug021001 nanoscience & nanotechnologytransmucosal drug deliveryBioavailabilitychemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliveryprodrug0210 nano-technology030217 neurology & neurosurgeryEx vivo
researchProduct

Adriamycin and Daunomycin in the Treatment of Vesical and Prostatic Neoplasias. Preliminary Results

1972

Our preHrninary experience with adriamycin in tumors of the bladder and prostate is of 25 treatments performed in 21 patients. The discrepancy between the numbers of patients and treatments is due to the fact that some patients were again submitted to various therapeutic cycles upon subsequent admissions. The treatments administered to the same patient at different times are considered individually, with regard either to a different schedule and way of administration of the drug, or to the interposition of other therapeutic means in the intervals between treatments. In addition, 13 patients were treated with daunomycin, as shown in Table 1.

DrugSchedulemedicine.medical_specialtybusiness.industrymedia_common.quotation_subjectBladder MucosaUrologymedicine.anatomical_structureProstateIntravesical instillationBladder tumorMedicinebusinessmedia_common
researchProduct

Carbamazepine transbuccal delivery: the histo-morphological features of reconstituted human oral epithelium and buccal porcine mucosae in the transmu…

2009

Transbuccal drug delivery is an attractive way of administration since several well-known advantages are provided, especially with respect to peroral management. Carbamazepine (CBZ) is an anticonvulsant which is useful in controlling neuropathic pain, and it is currently administered by peroral route, although its absorption and bioavailability is limited due to various factors. The oral cavity could be an interesting site for transbuccal CBZ delivery due to two properties: slow administration of constant low drug doses and less dose-related side effects. However, in transbuccal absorption a major limitation could be the low permeability of the mucosa which results in low drug bioavailabil…

DrugSwinemedicine.medical_treatmentmedia_common.quotation_subjectImmunologyAbsorption (skin)PharmacologyPermeabilitymedicineImmunology and AllergyAnimalsHumansmedia_commonPharmacologyChemistryMouth MucosaCarbamazepineBuccal administrationEpitheliumCarbamazepine Transbuccal drug delivery Porcine buccal mucosa Reconstituted human oral epithelium Trigeminal neuralgiaBioavailabilityAnticonvulsantmedicine.anatomical_structureCarbamazepineCheekDrug deliveryAnticonvulsantsmedicine.drugInternational journal of immunopathology and pharmacology
researchProduct

Solid and Semisolid Innovative Formulations Containing Miconazole-Loaded Solid Lipid Microparticles to Promote Drug Entrapment into the Buccal Mucosa

2021

The currently available antifungal therapy for oral candidiasis (OC) has various limita- tions restricting its clinical use, such as short retention time, suboptimal drug concentration and low patients compliance. These issues could be overcome using micro or nanotechnology. In par- ticular, solid lipid microparticles (SLMs) resulted as a particularly promising penetration enhancer carrier for lipophilic drugs, such as the antifungal miconazole (MCZ). Based on these considera- tions, cetyl decanoate (here synthesized without the use of metal catalysis) was employed together with 1-hexadecanol to prepare MCZ-loaded SLMs. These resulted in a powder composed of 45–300 µm diameter solid spheric…

Drugbuccal filmmedia_common.quotation_subjectPharmaceutical SciencemiconazoleBuccal mucosaArticleDosage formbuccal gelEntrapmentPharmacy and materia medicaoral candidiasismedicineex vivo studiemedia_commonChromatographycetyl decanoateChemistryex vivo studiesBuccal administrationPermeationoral candidiasiRS1-441mucosal deliverySettore CHIM/09 - Farmaceutico Tecnologico Applicativopenetration enhancersolid lipid microparticlebuccal mucosasolid lipid microparticlesMiconazoleEx vivomedicine.drugPharmaceutics
researchProduct

Galantamine delivery on buccal mucosa: permeation enhancement and design of matrix tablets

2009

The most important feature in transbuccal drug delivery is the low drug passage through the buccal mucosa. In our previous work we demonstrated the aptitude of Galantamine to penetrate the buccal tissue. The collected data suggested that Galantamine passively crosses the membrane, but the calculated Js and Kp values showed that the drug amount that crosses the membrane wasn’t sufficient to assure blood therapeutic level. So, in this study, ex vivo permeation tests, using porcine buccal mucosa, were performed in presence of physical or chemical enhancers. No significant differences in penetration rate were observed using chemical enhancers as sodium dehydrocholate, EDTA disodium salt and tri…

Drugbusiness.industrymedia_common.quotation_subjectPharmaceutical ScienceBuccal administrationPharmacologyPermeationBuccal mucosaDosage formstomatognathic systemSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliveryGalantamineMedicineTransbuccal delivery Galantamine Permeation enhancement Alzheimer’s diseasebusinessEx vivomedicine.drugmedia_common
researchProduct